Loading...
Loading...
Acorda Therapeutics
ACOR today announced that it has
named Jane Wasman as President, International. Ms. Wasman most recently
has served as Acorda's Chief, Strategic Development and General Counsel.
In her new role, Ms. Wasman will lead the Company's efforts to identify
and launch in-licensing and commercial opportunities outside the United
States. She will also be responsible for managing Acorda's collaboration
with Biogen Idec
BIIB in their international development and
commercialization of FAMPYRA® (prolonged-release fampridine
tablets). Ms. Wasman will also continue to lead the Company's global
strategic development and will retain the title of General Counsel and
Corporate Secretary.
“I am delighted that Jane will be spearheading our proactive efforts to
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in